Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
Annette Langer‐Gould, Jessica B. Smith, Edlin Gonzales, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 25

Showing 25 citing articles:

Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections
Annette Langer‐Gould, Bonnie H. Li, Jessica Smith, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 23
Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges
Kamran Sheikhi, Sara Ghaderi, Hassan Firouzi, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access | Times Cited: 1
The Potential Capacities of FTY720: Novel Therapeutic Functions, Targets, and Mechanisms against Diseases
Juan Liu, Lu Zhang, Le Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117508-117508
Open Access | Times Cited: 1
Multiple sclerosis and COVID-19: interactions and unresolved issues
Ana Zabalza, Alan J. Thompson, Dalia Rotstein, et al.
The Lancet Neurology (2025) Vol. 24, Iss. 4, pp. 361-370
Closed Access | Times Cited: 1
Intruders or protectors – the multifaceted role of B cells in CNS disorders
James W. Aspden, Matthew A. Murphy, Rommi D. Kashlan, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 5
MS treatment de-escalation: review and commentary
Krzysztof Selmaj, Hans–Peter Hartung, Marcin P. Mycko, et al.
Journal of Neurology (2024) Vol. 271, Iss. 10, pp. 6426-6438
Open Access | Times Cited: 5
Myasthenia gravis in 2025: five new things and four hopes for the future
Sophie Binks, I. M. Morse, Mohammad Ashraghi, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Open Access
Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies
Alexandra Balshi, Grace Leuenberger, John Dempsey, et al.
Neurology Clinical Practice (2025) Vol. 15, Iss. 2
Closed Access
Management of hepatitis B virus (HBV) infection in multiple sclerosis patients on disease modifying therapies (DMTs)
Antonio Riccardo Buonomo, Giulio Viceconte, Laura Ambra Nicolini, et al.
Future Virology (2025), pp. 1-10
Open Access
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Federica Galota, Simone Marcheselli, Sara De Biasi, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 606-606
Open Access
Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort
S Nobile, Philippe Beauchemin
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024) Vol. 51, Iss. 6, pp. 811-818
Open Access | Times Cited: 3
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis
Robert Gross, John R. Corboy
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 341-353
Closed Access | Times Cited: 3
Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review
Hibba Yousef, Brigitta Malagurski Tortei, Filippo Castiglione
Journal of Neurology (2024)
Open Access | Times Cited: 3
Sleep and cognitive outcomes in multiple sclerosis; a systematic review
Behnam Golabi, Hadis Razmaray, Sepideh Seyedi‐Sahebari, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
An updated systematic review and meta-analysis exploring the efficacy and safety of dimethyl fumarate (DMF) for patients with multiple sclerosis (MS)
Hossam Tharwat Ali, Abdelmottaleb A. Yousef, Sara Hosny El-Farargy, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 2, pp. e000872-e000872
Open Access | Times Cited: 2
Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis
Vivien Li, Michele D. Binder, Anthony W. Purcell, et al.
Journal of Neuroimmunology (2024) Vol. 390, pp. 578347-578347
Closed Access | Times Cited: 1
Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients
Hilde Marie Torgauten, Therese Bredholt Onyango, Sonja Ljostveit, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 89, pp. 105770-105770
Closed Access | Times Cited: 1
Data-driven risk/benefit estimator for multiple sclerosis therapies
Bibiana Bielekova, Tianxia Wu, Péter Kósa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis
Marco Vercellino, Stella Marasciulo, Emanuela Ricotti, et al.
Multiple Sclerosis Journal (2024)
Closed Access
Features of the vaginal microbiota in women with relapsing-remitting multiple sclerosis
Е. И. Лузанова, М. И. Карпова, О. С. Абрамовских, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 17, pp. 58-65
Open Access
Aging and infectious diseases in myasthenia gravis
Vera Bril, Nils Erik Gilhus
Journal of the Neurological Sciences (2024) Vol. 468, pp. 123314-123314
Open Access
Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis treated with low‐dose natalizumab following fingolimod
Masami Tanaka, Kazuo Nakamichi, Keiko Tanaka
Clinical and Experimental Neuroimmunology (2024)
Closed Access
Antibiotic Utilization Among People With Multiple Sclerosis in the Netherlands, 2018–2020
Melissa Wing Yee Leung, Marloes T. Bazelier, Bernard M.J. Uitdehaag, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 12
Open Access
Comparative Effectiveness of Rituximab and Cladribine in Relapsing-Remitting Multiple Sclerosis: A Target Trial Emulation
Brit Ellen Rød, Einar A. Høgestøl, Øivind Torkildsen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Ageing and multiple sclerosis
Julija Isačenko, Renata Balnytė
Neurologijos seminarai (2024) Vol. 28, Iss. 2(100), pp. 92-99
Open Access
Page 1

Scroll to top